Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of AT247 vs NovoRapid and Fiasp in T1DM
NCT03959514Phase 1Completed
- Sponsor
- Arecor Therapeutics
- Start
- Apr 2019
- Primary completion
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AT247 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Arecor Therapeutics. Primary endpoint: Area under the glucose infusion rate-time curve of insulin aspart 0-60 minutes. Started Apr 2019; status: completed.
02
Drugs
AT247
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03959514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959514.